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Abstract
INTRODUCTION: Peptide vaccines offer anti-tumor efficacy with very low toxicity. However,
repeat stimulation with an immunogenic peptide leads to activation induced cell death (AICD),
decreasing efficacy. We engineered variants of an immunogenic peptide (E39) and tested their
ability to induce a robust, sustainable immune response.
METHODS: Multiple variants of E39 were created by exchanging 1 or 2 amino acids. We tested the
PBMC proliferation, cytokine production and cytolytic activity induced by each variant peptide.
RESULTS: Repeated stimulation with E39 likely led to in vitro AICD, while stimulation with E39’ led
to T-cell proliferation with less evidence of AICD, modest cytokine production and high CTL
activity.
CONCLUSIONS: E39’ appears to be the optimal variant of E39 for inducing effective long-term
immunity.
Key words: Folate binding protein, folate receptor alpha, J65, E39, E39’.

Introduction
Treatment of cancer has significantly expanded
beyond the traditional management strategies of
chemotherapy, radiation, and surgery, with
immunotherapy becoming increasingly important.
Within this field, there is considerable interest in
developing strategies for prevention of cancer
recurrence after standard of care treatment using
therapies that induce adaptive immunity against a
specific tumor-associated antigen (TAA). We have
previously published our successful attempts to
induce such a response to a well-known TAA, HER2,
using immunogenic epitopes, specifically E75 and

GP2. These peptides form the basis of vaccines that
strive to stimulate production of cytotoxic T
lymphocytes (CTLs) that are specific to the antigen
and, thus, capable of targeted lysis of tumor cells.[1-5]
In addition to an initial production of CTLs, memory
T cells are produced, which maintain immune
surveillance and offer the promise of prolonged
disease-free survival when these vaccines are given in
the adjuvant setting.[6,7] With our most successful
peptide vaccine, NeuVax, now in a phase III trial for
FDA approval, the identification of additional TAAs
to target for similar vaccines is ongoing.
http://www.jcancer.org
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Folate binding protein (FBP), also known as
folate receptor alpha, is a near ideal TAA for
immunotherapy. FBP is over-expressed in over 90% of
ovarian and 20-50% of breast cancers, yet is rarely
expressed in normal tissues [8]. Analogous to HER2 in
breast cancer, the level of FBP expression has been
found to be greater than 20-fold higher in malignant
cells compared to normal cells, and its
over-expression is linked to more aggressive
cancers.[3] Not only is FBP expression increased in
cancer cells, it is also inherently immunogenic; it has
been recognized by CTLs isolated from ovarian and
breast cancer patients and shown to induce
tumor-specific cytokine release and cytolysis [4-9].
While the body of literature studying FBP-directed
immunotherapies is limited, the combination of
frequent over-expression in cancer cells, correlation
with aggressive disease, and natural immunogenicity
make FBP an attractive TAA for use in peptide
vaccines.
We have previously shown that FBP peptides
were recognized by HLA-A2+ ovarian and breast
tumor associated lymphocytes that were not
previously subjected to in vitro antigen stimulation.[4]
Upon further investigation, E39 (FBP191-199,
EIWTHSYKV) was the most consistently recognized
of these HLA-A2 restricted antigenic epitopes within
the FBP.[6] Furthermore, E39-stimulated TALs from
ovarian cancer patients recognized allogeneic,
HLA-A2 positive, FBP-expressing ovarian cancer cells
and induced cell lysis of these and other
FBP-expressing epithelial tumor cells of the colon and
pancreas.[4] Knowing the potential of E39 to function
as an immunodominant epitope, we are conducting a
phase I/IIa trial, in which HLA-A2 positive patients
are given varying doses of E39 with GM-CSF. At the
time of interim analysis, the vaccine was very well
tolerated and induced a strong, dose-dependent
immune response. Early efficacy results showed a
statistically significant increase in estimated 2-year
DFS for patients receiving an optimal dose of the
vaccine over controls and patients receiving lower
doses [10].
Given our success with peptide vaccines and
promising early results with E39, we anticipate future
trials to better assess its clinical efficacy. There are
growing concerns, however, that repeated stimulation
with one immunogenic peptide, such as E39, may
actually impair immune memory, which is the
ultimate goal of any peptide vaccine. Although the
exact mechanisms are not fully understood, this
overstimulation seems to adversely affect CTL
selection and proliferation. It has been shown that
peptide stimulation produces a polyclonal CTL
response, with only some of these CTL populations

becoming the effector and memory CTLs necessary
for effective long-term immune surveillance.
Over-stimulation with an immunogenic peptide may
lead to activation induced cell death (AICD) of these
highly desired cells [11]. If this process is repeated
with continued stimulation, it can lead to weaker
responses each time. A strategy of inoculating
patients with an attenuated peptide has been
proposed as a way to minimize this risk of AICD, but
the effect on T cell selection and expansion is
unknown. Our early work with the new E39 peptide
affords us the opportunity to test these theories.
To this end, we engineered multiple attenuated
peptides by substituting one or two amino acids of the
wild-type peptide, E39. We then tested the attenuated
peptides for in vitro immunologic responses. Our
hypothesis was that these attenuated peptides, once
bound to the HLA molecule, would lead to altered
interactions with the T cell receptor (TCR) and
ultimately to proliferation of different populations of
CTLs. In this report, we describe the identification of
E39’ as the ideal attenuated version of E39 through
discovery of its in vitro potential as a primer of a
robust, sustainable immune response against FBP.

Methods
Peptide Creation
Multiple variants of the E39 peptide were
produced by exchanging one or two amino acids;
these peptides and their amino acid sequence are
displayed in Table 1. DNAStar software predicted that
reducing the positive charge of the amino acid in
position 5 and removing the phenolic structure at
position 7 would improve the flexibility of residues
5-9 and allow for a better fitting of the TCR with the
peptide-MHC complex. Specifically, the flexibility of
the peptide is improved by reducing the positive
charge at the amino acid in position 5 (histidine)
through
replacement
with
phenylalanine.
Phenylalanine is not charged and its benzene
aromatic ring is a close substitution for the imidazole
ring of histidine. Then, the phenolic structure of
tyrosine was replaced with the aliphatic core chain of
threonine. Both tyrosine and threonine contain a
hydroxyl side chain group. Thus, the positive charge
in position 5 and the rigid structure in position 7 were
eliminated in the creation of E39’ by changing
histidine to phenylalanine at position 5 and tyrosine
to threonine at position 7. J77 and J78 each had only
one of these key substitutions. The remaining
peptides were created with variations on these two
changes, some with additional substitutions at
position 1 designed to alter the HLA binding. An
Applied Biosystems Model 430A peptide synthesizer
http://www.jcancer.org
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used solid-phase synthesis to produce the epitopic
peptides.
Table 1. E39 variant peptides and amino acid sequences.
Peptide
E39
J63
J64
E39'
J66
J67
J68
J77
J78

Amino Acid Sequence
EIWTHSYKV
FIWTHSTKV
GIWTHSTKV
EIWTFSTKV
FIWTFSTKV
EIWTHATKV
FIWTFATKV
EIWTHSTKV
EIWTFSYKV

T2 Stabilization Assay
To evaluate the HLA-A2 binding strength of
each peptide, cell line T2 cells were cultured overnight
in RPMI 1640 medium in the presence of saturating
quantities (100µg/ml) of a single variant peptide (J78 ,
J77 , E39’ , J64 , J63 , J66 , J67 or J68). The cells were
then stained with a monoclonal antibody, BB7.2, used
to recognize the bound, HLA-A2 molecule. The level
of expression of the peptide-bound HLA-A2 complex
was measured by the average fluorescent intensity,
the mean channel fluorescence (MCF), using flow
cytometry.

non-adherent fresh PBMCs were added. IL-12 (100
pg/m) was added after two additional hours of
incubation. Then, IL-2 was added to a final
concentration of 150 IU/ml, 24-36 hours later. Cells
were maintained in culture for 7 days in the presence
of 100 IU/ml of exogenous IL-2. Thereafter, cells were
washed, rested for 24 hours in complete RPMI
medium without IL-2. This procedure was repeated
for a total of 3 weekly priming sessions for each
peptide.

Cell Proliferation
PBMC cultures from six different healthy or
naïve, HLA-A2-positive donors were primed with a
single dose of E39 or an attenuated E39 variant (J77,
J78, E39’) weekly as described above. The total
number of cells was counted after a week in culture
and just prior to the next week’s priming.

Interleukin-2 (IL-2) Production
Those peptides able to effectively stimulate
PBMC proliferation (J77, E39’) were then tested for the
ability to stimulate IL-2 production as compared to
E39 and a control. PBMCs were primed weekly for
three weeks with either a control of no protein (NP),
E39, J77, or E39’ in the previously described method.
For three days after the third priming, IL-2
concentrations were measured in supernatant.

In vitro Immune Monitoring

Interferon-γ (IFN-γ) Release Assay

Peripheral Blood Mononuclear Cells (PBMCs)
were isolated from multiple healthy donors,
separated into the plastic-adherent and non-adherent
fractions. The different fractions were then prepared
as described below. The non-adherent fraction
contained
95%
CD3
positive
cells.
The
plastic-adherent PBMCs were cultured in complete
RPMI 1640 medium containing 10% Fetal Calf Serum
(FCS), granulocyte-macrophage colony-stimulating
factor (GM-CSF), and IL-4 for 5 days. These cell
cultures resulted in immature monocyte-derived
dendritic cells (iDCs). Plastic-adherent and
non-adherent PBMCs were stored frozen in liquid
nitrogen until use.
The PBMCs were primed with the E39 or a
variant peptide; first with 500,000 iDCs plated in 24
1.0 ml well plates with complete RPMI medium and
allowed to attach for 2-3 hours. The complete RPMI
medium was removed and replaced with serum-free
RPMI medium. Peptides were added to the wells for a
final concentration of 10µg/ml. One ml RPMI 1640
medium containing 20% FCS was added to the wells.
After 2 hours of incubation at 37C, 3 × 106 of

Next, the amount of IFN-γ produced was
assessed following PBMC stimulation with different
methods. PBMCs from healthy donors were primed
once a week for three weeks with E39’ or E39 as
described above. The PBMCs stimulated with E39’
were then targeted against T2 cells loaded with E39,
J77, or E39’. PBMCs primed with E39 were only tested
against cells loaded with E39. IFN-γ release into the
supernatant of each set of PBMC cultures was
measured over two days.

Cytotoxicity Assays
Finally, PBMC cultures were tested for their
ability to lyse cells loaded with FBP peptides. Primed
PBMCs were targeted against 51Chromium labeled, T2
cells loaded with three concentrations (0, 5, 25 µg/ml)
of the appropriate peptide. The percent lysis was
calculated by the amount of free 51Chromium in
supernatant as measured after 5 hours. The PBMC
were primed and the T2 cells loaded in the same
fashion as the IFN-γ assays; E39’-primed cells were
tested against T2 cells loaded with E39, E39’, or J77,
while E39-primed PBMCs were tested only against
E39.

http://www.jcancer.org
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Results
T2 Stabilization Assay
All of the variant peptides were able to bind the
HLA-A2 molecule as indicated by a MCF greater than
the control (Figure 1). As expected, peptides with a
substitution at position 1 (J63, J64, J66 and J68)
demonstrated high affinity for the HLA-A2 molecule
(198, 199, 186, and 202 MCF, respectively). Those
peptides did not undergo further investigation as
their higher affinity for the HLA-A2 molecule was not
consistent with the goal of an attenuated peptide.
Peptides created with only substitutions in positions 5
and 7 (E39’, J77 and J78) were all able to bind the
HLA-A2 molecule. J78’s affinity for HLA-A2 did not
differ significantly from that of E39 (127 v 125 MCF).
J77 and E39’ had much weaker binding, with 78 and
65 MCF, respectively.

the opposite response with decrease cell counts
between days 7 and 14, likely representing AICD. The
J77 and J78 primed PBMCs had a similar, low-level
response in this patient with expansion to 6.5 x106 and
6.8 x106 cells, respectively. Because J78 did not exhibit
a consistent ability to induce PBMC proliferation, it
was precluded from further studies.

Figure 2. PBMC proliferation after stimulation with E39 or E39 derived
epitopes; Donor #1.

Figure 1. HLA-A2 stabilization of E39-derived attenuated epitopes

In vitro Immune Monitoring
Cell Proliferation
The PBMC proliferation potential of E39’, J77,
and J78 was measured over six cultures from multiple
different, healthy, HLA-A2 positive donors;
representative data from two of these donors are
shown in Figures 2 and 3, respectively. Figure 2 shows a
representative graph of cell counts one week after
each of three weekly stimulations. In this case, E39
and E39’ resulted in the highest expansion to 11.9 x106
cells and the increase continued to four weeks with
both peptides. J77 and J78 did not invoke improved
cell proliferation compared to NP. In Figure 3, PBMC
proliferation from another donor that underwent
similar priming is shown, but the data instead
represent cell counts 7 to 14 days after the third
priming with each respective peptide. Cells primed
with E39’ continued to proliferate from 6.1 x106 to 9.1
x106 cells between 7 to 14 days. Conversely, PBMCs
primed with the highly immunogenic E39 underwent

Figure 3. PBMC proliferation after stimulation with E39 or E39 derived
epitopes; Donor #2.

IL-2 Production
IL-2 production was measured for E39 and the
attenuated peptides that consistently resulted in
PBMC proliferation (E39’ and J77; Figure 4). At three
days out from the third stimulation with J77, there
was no increase in IL-2 production. In response to
both E39 and E39’ priming, however, there was a
significant increase in IL-2. Importantly, stimulation
with E39’ produced less IL-2 than E39 (611 and 844
pg/ml, respectively). Because J77 primed PBMCs did
not produce IL-2, it was precluded from further
testing except as a target peptide of for E39 and
E39’-primed PBMCs.
http://www.jcancer.org
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Interferon-γ Release Assay
The IFN-γ release after priming with E39 and
E39’ was measured as described above and is
displayed in Figure 5. E39’-primed cells recognized all
FBP peptide variants on re-stimulation with
peptide-loaded T2 cells as evidence by initial IFN-γ
release. Those E39’-primed PBMCs re-stimulated with
E39’ had the smallest response; 48% and 0% from
baseline on days 1 and 2, respectively. The
E39’-primed PBMCs stimulated with J77 had a small,
yet stable response with a 57% and 43% increase from
baseline on days 1 and 2, respectively. The
E39’-primed, E39-stimulated (E39’, E39) population
maintained a stable, moderate response with a 99%
and 102% increased from baseline on day 1 and 2. The
highest IFN-γ release was seen in E39-primed PBMCs
targeted against E39-loaded T2 cells, with an increase
of 184% from baseline on days 1 and 2.

variants. The lowest response occurred when
targeting J77-loaded cells (4.2 and 8.2% at 5 and 25
µg/ml). The other two populations of E39’-primed
cells showed impressive cytotoxicity, with 24.5% and
17.4% lysis of E39-loaded cells and 20.9% and 23.2% of
E39’-loaded cells at 5 and 25 µg/ml, respectively. The
E39-primed PBMCs targeted at E39 did not perform
as well as these two groups of E39’-primed cells.
E39-primed cells lysed only 11.1% and 14.6% of
E39-loaded T2 cells at 5 and 25 µg/ml, respectively.

Figure 6. % specific lysis of CTLs after three weekly E39’ or E39 priming doses
at different concentrations (0, 5 or 25µg/ml) followed by a single E39’, E39, or
J77 boosting.

Figure 4. Interleukin 2 (IL-2) levels produced by PBMCs after third priming
with E39’ E39, and J77.

Figure 5. IFN-γ levels in PBMCs after three weekly stimulations with E39’ or
E39, followed by a fourth re-stimulation with either E39’, E39, or J77.

Cytotoxicity Assays
The percent specific lysis of peptide-loaded T2
cells produced by the combinations described above
is displayed in Figure 6. As expected, loading cells
with 0 µg/ml concentration of peptides produced no
response in all sequences. E39’-primed PBMCs
recognized and lysed T2 cells loaded with all FBP

Discussion
In this study of variant peptides created from
E39, we found that the candidate peptides, J78, J77
and E39’, were able to stably bind the HLA-A2
molecule. When these peptides were tested for the
ability to induce PBMC proliferation, E39’ consistently
showed the best results, particularly over multiple,
repeated T cell stimulations. Interestingly, while E39
induced a robust initial proliferation, some
populations of cells contracted after continued
priming with E39, indicating significant AICD. We
then tested cells primed with E39 and E39’ for
functionality finding that cells primed by E39
produced high amounts of IL-2 and IFN-γ, while
those primed by E39’ made more moderate amounts
of each cytokine. Lastly, E39’-primed cells showed
excellent cytotoxicity when targeted to both E39 and
E39’ loaded T2 cells, and actually performed better
than cells primed with the wild type peptide, E39.
Cumulatively, these findings suggest that an
attenuated version of a strong T cell epitope can help
preserve the lytic CTLs in repeatedly stimulated T cell
populations.
While there have been great strides made toward
the goal of a successful peptide vaccines able to
http://www.jcancer.org
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induce a long-term, adaptive anti-tumor response, the
final goal is yet to be reached. Multiple investigators
have been able to induce anti-tumor T cell responses
ex vivo, but clinical responses are often disappointing.
Part of the reason for these disappointing results
seems to be early elimination of the final effectors of
these vaccines, the peptide-specific CTL capable of
tumor lysis.[12] There is concern that the repeated
stimulation with a strongly immunogenic peptide is
actually inducing AICD. A new strategy of
inoculating patients with a weaker or attenuated
version of a specific peptide has the potential to avoid
this issue.
With this strategy in mind, we set out to produce
an attenuated version of E39, a known immunogenic
peptide, and test the immune response it would
induce as compared to E39. Multiple novel peptides
were created, with three potential candidates that
possessed altered amino acids within the TCR binding
site. These three peptides were all shown to bind the
HLA-A2 molecule. Next, we tested how these
peptides would stimulate PBMC proliferation,
particularly through multiple rounds of stimulation.
E39’ consistently performed better than any other
attenuated peptide and nearly as well as E39 at initial
stimulation (Figure 2). The more interesting finding,
however, was noted after watching continued
proliferation two weeks after a third priming (Figure
3). Here, E39-induced PBMC proliferation fell off
significantly in the second week, while cells primed
by E39’continued to expand in number This graphic is
representative of similar findings from additional
PBMC populations tested in this study and is a
common phenomenon observed with repeated
stimulation with one, immunogenic peptide. The late
drop-off of PBMCs likely corresponds to the very
AICD suspected following continual stimulation with
E39. The proliferation shown with E39’, however, is
very encouraging and indicates that the attenuated
peptide did not induce AICD, perhaps by avoiding
over-stimulation.
While this proliferation data was encouraging,
further testing was needed to determine the
functionality of the induced T cell populations. To test
this, we first measured cytokine production after
PBMC stimulation with E39 and E39’. E39’ resulted in
blunted cytokine production as compared to E39, as
demonstrated in assays of IL-2 and IFN-γ production.
These higher cytokine levels in response to E39 may
simply occur because E39 is a stronger signal to T
cells, but may also be related to selection of certain T
cell populations after repeated stimulation.

1260
While E39’ led to less AICD, it was unclear how
the reduced binding affinity and cytokine response
would alter the ability to mediate tumor cell death.
The CTL response that is induced by a pathogen or by
an immunogenic peptide is understood to be
polyclonal, with some cells differentiating to produce
cytokines and others, the effector cells, to perform cell
lysis. Even within the effector cells, there are
short-lived effector cells and memory precursor
effector cells.[13] The differentiation, proliferation and
apoptosis of these varying T cell populations are
controlled by a complex interplay of cytokines and
interactions between the TCR and the peptide-HLA
complex. While this process is not fully understood,
cells with high affinity TCRs seem to be the most
effective at lysing target cells and are most likely to
become memory T cells.[11,14] Thus, the ability to
induce these high TCR affinity T cells specific for the
target TAA is key to the success of peptide vaccines.
High levels of IFN-γ have been linked to a weaker
TCR signal caused by low affinity of the TCR to the
HLA-peptide complex and this weak TCR signal has
been shown to lead to early contraction of effector
CTL populations.[14,15] Similarly, while IL-2 is
needed for CTL proliferation, high levels have been
linked to production of regulatory T cells that may
hinder effective clearance of targeted cancer cells.
Multiple, strong stimulations with E39 may,
theoretically, have led to AICD of highly cytolytic
effector CTLs and instead selected for T cells that
focus more on cytokine production, accounting for the
high levels of IFN-γ and IL-2.
The cytolytic assays demonstrated that
E39’-primed cells were capable of lysing cancer cells
loaded with any of the three FBP peptides tested.
These cells performed best when targeting cells
loaded with E39’, but they were also able to lyse a
high number of cells loaded with E39. More
importantly, these E39’-primed cells had higher
peptide-specific cell lysis than E39-primed cells. After
over-stimulation
with
E39,
the
apoptosis
demonstrated by the PBMC proliferation tests seems
to have affected mainly effector CTLs, leaving behind
cell populations with low TCR affinity that produce
high levels of IL-2 and IFN-γ release, but have
decreased CTL activity. Less potent stimulation with
E39’, on the other hand, did not seem to induce the
same degree of effector CTL AICD, maintaining
populations of CTLs with high TCR affinity. This is
ideal, as these cells are thought to not only be effective
at target cell lysis, but are also thought to become
memory T cells.

http://www.jcancer.org
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Figure 7. Proposed mechanism of improved T cell response after repeated stimulation with attenuated peptide (E39’) and parent peptide (E39).

Figure 8. Phase I/2a trial design in breast and ovarian cancer (NCT02019524)16

The findings of this trial support the theory that
stimulation with an attenuated peptide, E39’, could
lead to a more effective cancer vaccine (as depicted in
Figure 7). Whether this peptide will be most effective
alone or in combination with the more

immunodominant parent peptide, E39, will be the
focus of our next trial. We have started a Phase Ib trial
in breast and ovarian cancer patients with
FBP-expressing tumors. The trial design incorporates
three arms for the primary vaccine series consisting of
http://www.jcancer.org
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six inoculations: one arm with all inncoulations being
E39, another with the first three inoculations with E39
followed by three with E39’, and the last with E39’
given first, followed by E39. Once patients have
completed their primary vaccine series, their residual
immunity will be measured in vivo and in vitro and
they will be classified as significant responders or
non-responders. Patients will then be randomized
again to receive either E39 or E39’ in a four arm
booster series (Figure 8). The primary objectives are to
determine the most effective method to maximize
short-term and long-term FBP-specific immunity, to
determine the most effective booster inoculations to
maintain FBP-specific immunity, and to evaluate the
safety of the vaccination series. This currently
enrolling study (NCT02019524) will allow us to use
different sequences of the wild type peptide (E39) and
attenuated peptide (E39’) in order to answer these
novel and important research questions in the field of
immunotherapy.[16] If successful, the application of
this novel strategy using a native peptide in
combination with an attenuated version could be
far-reaching.

Conclusion
In summary, these experiments demonstrate that
repeated stimulation with highly immunogenic E39
likely leads to AICD of T cells populations in vitro
including peptide-specific effector CTLs with high
affinity TCRs. E39’ appears to be the optimal variant
of E39 as it consistently results in T cell proliferation,
stimulates T cells to produce modest cytokines and,
most importantly, selects for effector CTLs with high
TCR affinity that are necessary for tumor cell lysis.
The potential of this version of E39 to induce an
enduring, cytolytic anti-FBP immune response that
results in tumor cell lysis is currently being evaluated
in a phase Ib clinical trial in ovarian and breast cancer
patients.

Competing Interests
The authors have declared that no competing
interest exists.

References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.

12.
13.
14.
15.
16.

Peoples GE, Goedegebuure PS, Andrews JV, et al. HLA-A2 presents shared
tumor-associated antigens derived from endogenous proteins in ovarian
cancer. J Immunol. 1993; 151(10): 5481-5491.
Yoshino I, Goedegebuure PS, Peoples GE, et al. HER2/neu-derived peptides
are shared antigens among human non-small cell lung cancer and ovarian
cancer. Cancer Res. 1994; 54(13): 3387-3390.
Li PY, Del Vecchio S, Fonti R, et al. Local concentration of folate binding
protein GP38 in sections of human ovarian carcinoma by in vitro quantitative
autoradiography. J Nucl Med. 1996; 37(4): 665-672.
Peoples GE, Anderson BW, Lee TV, et al. Vaccine implications of folate
binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in
epithelial cancers. Clin Cancer Res. 1999; 5(12): 4214-4223.
Peoples GE, Anderson BW, Fisk B, et al. Ovarian cancer-associated
lymphocyte recognition of folate binding protein peptides. Ann Surg Oncol.
1998; 5(8): 743-750.
Kim DK, Lee TV, Castilleja A, et al. Folate binding protein peptide 191-199
presented on dendritic cells can stimulate CTL from ovarian and breast cancer
patients. Anticancer Res. 1999; 19(4B): 2907-2916.
Ioannides CG, Platsoucas CD, Rashed S,et al. Tumor cytolysis by lymphocytes
infiltrating ovarian malignant ascites. Cancer Res. 1991; 51(16): 4257-4265.
Garin-Chesa P, Campbell I, Saigo PE, et al. Trophoblast and ovarian cancer
antigen LK26. Sensitivity and specificity in immunopathology and molecular
identification as a folate-binding protein. Am J Pathol. 1993; 142(2): 557-567.
Linehan DC, Goedegebuure PS, Peoples GE, et al. Tumor-specific and
HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human
metastatic breast cancer. J Immunol. 1995; 155(9): 4486-4491.
Greene JM, Schneble EJ, Berry JS. Preliminary Results of the Phase I/IIa Dose
Finding Trial of a Folate Binding Protein Vaccine (E39+GM-CSF) in Ovarian
and Endometrial Cancer Patients. J Clin Oncol. 2015; 33(suppl): abstr e14031.
Kawano K, Efferson CL, Ioannides CG. Sensitivity of Undifferentiated,
High-TCR Density CD8+ Cells to Methylene Groups Appended to Tumor
Antigen Determines Their Differentiation of Death. Cancer Research. 2005;
65(70): 2930-37.
Chhabra, A. Mitochondria-centric activation induced cell death of cytolytic T
lymphocytes and its implications for cancer immunotherapy. Vaccine. 2010;
28: 4566-4572.
Boulet S, Daudelin JF, Labrecque N. IL-2 Induction of Blimp-1 Is a Key In Vivo
Signal for CD8+ Short-Lived Effector T Cell Differentiation. J Immunol. 2014;
193: 1847-54.
Stoycheva D, Deiser K, Starck L, et al. IFN-γ Regulates CD8+ Memory T Cell
Differentiation and Survival in Response to Weak, but Not Strong, TCR
Signals. J Immunol. 2015; 194: 553-559.
Matsueda S, Gao H, Ioannides C. N-Terminally LRMK-linked HER-2 peptides,
AE-37 and AE-47, Aid Differentiation of E75-TCR+CD8+ Cells to
Perforin-positive Cells. Anticancer Research. 2009; 29: 2427-2436.
[Internet]
https://www.clinicaltrials.gov/ct2/show/NCT02019524?term=
NCT02019524.

Acknowledgements
We greatly appreciate all the work of Dr.
Constantin Ioannides and the personnel from his lab
which made this project possible.

Disclaimer
The view(s) expressed herein are those of the
author(s) and do not reflect the official policy or
position of San Antonio Military Medical Center, the
U.S. Army Medical Department, the U.S. Army Office
of the Surgeon General, the Department of the Army,
Department of Defense or the U.S. Government.

http://www.jcancer.org

